Keros Therapeutics (KROS) Other Non Operating Income (2019 - 2025)
Keros Therapeutics posted quarterly Other Non Operating Income of $273000.0 for Q4 2025, up 219.21% year-on-year from $85522.6 in Q4 2024, and up 207.91% on a QoQ basis from -$253000.0 in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Other Non Operating Income data on file, last reported at $273000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income rose 219.21% year-over-year to $273000.0; the trailing twelve-month figure through Dec 2025 stood at -$539000.0 (up 43.5% YoY), and the FY2025 full-year result was -$539000.0, up 43.5% from the prior year.
- Other Non Operating Income for Q4 2025 stood at $273000.0, up from -$253000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $762000.0 in Q3 2022 and bottomed at -$1.4 million in Q4 2022.
- The 5-year median for Other Non Operating Income is -$96500.0 (2021), against an average of -$134750.0.
- Peak annual rise in Other Non Operating Income reached 656.2% in 2022, while the deepest fall reached 1288.12% in 2022.
- A 5-year view of Other Non Operating Income shows it stood at -$101000.0 in 2021, then sank by 1288.12% to -$1.4 million in 2022, then surged by 103.99% to $56000.0 in 2023, then plunged by 508.93% to -$229000.0 in 2024, then surged by 219.21% to $273000.0 in 2025.
- The last three Other Non Operating Income figures came in at $273000.0 (Q4 2025), -$253000.0 (Q3 2025), and -$221000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 273,000.00 |
| Sep 30, 2025 | -253,000.00 |
| Jun 30, 2025 | -221,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -229,000.00 |
| Sep 30, 2024 | -92,000.00 |
| Jun 30, 2024 | -196,000.00 |
| Mar 31, 2024 | -437,000.00 |
| Dec 31, 2023 | 56,000.00 |
| Sep 30, 2023 | -67,000.00 |
| Jun 30, 2023 | -155,000.00 |
| Mar 31, 2023 | -40,000.00 |
| Dec 31, 2022 | -1.40 Mn |
| Sep 30, 2022 | 762,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | -59,000.00 |
| Dec 31, 2021 | -101,000.00 |
| Sep 30, 2021 | -137,000.00 |
| Jun 30, 2021 | -80,000.00 |
| Mar 31, 2021 | -65,000.00 |
| Dec 31, 2020 | 156,000.00 |
| Sep 30, 2020 | -86,000.00 |
| Jun 30, 2020 | 158,000.00 |
| Mar 31, 2020 | -68,000.00 |
| Dec 31, 2019 | 56,000.00 |
| Sep 30, 2019 | 15,000.00 |
| Jun 30, 2019 | 69,000.00 |
| Mar 31, 2019 | 101,000.00 |